Published in Biotech Business Week, March 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Neose Technologies.
Report 1: Neose Technologies, Inc. (NTEC) received approval from Swissmedic, the Swiss Agency for Therapeutic Products, for the initiation of a Phase II human trial for NE-180.
Clinical trial supplies have been shipped, and patient recruitment has commenced. NE-180 is a long-acting, GlycoPEGylated erythropoietin being developed for the treatment of anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy and for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.